Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | SOD1 | P00441 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2256630 | 0.87 | DAO (0.54) | DAOALDH1A1NPSR1PDE3BPDE3A | |
| SCHEMBL21981585 | 0.84 | DAO (0.51) | DAOALDH1A1NPSR1MAPTMEN1 | |
| SCHEMBL4663323 | 0.84 | PDE3B (0.45) | DAOALDH1A1NPSR1PDE3BPDE3A | |
| SCHEMBL2251668 | 0.82 | ALDH1A1 (0.56) | ALDH1A1NPSR1MAPTMEN1LMNA | |
| SCHEMBL2253149 | 0.82 | SLC6A4 (0.41) | DAOALDH1A1NPSR1PDE3BPDE3A | |
| SCHEMBL2254318 | 0.81 | ERAP1 (0.51) | DAOALDH1A1NPSR1MAPTLMNA | |
| SCHEMBL2257545 | 0.81 | MEN1 (0.44) | DAOALDH1A1NPSR1MAPTMEN1 | |
| SCHEMBL2253443 | 0.81 | DAO (0.41) | DAOALDH1A1NPSR1MEN1KMT2A | |
| SCHEMBL2255065 | 0.81 | DAO (0.48) | DAOALDH1A1NPSR1 | |
| SCHEMBL2251697 | 0.80 | DAO (0.50) | DAOMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989424-B2 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7956041-B2 | antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide | AJINOMOTO CO., INC. (JP) | 2011-06-07 | — | — | US | disclosed |
| EP-2163555-A1 | New pyrazole derivatives and diabetic medicine containing them | Ajinomoto Co., Inc. (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-20100063124-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | AJINOMOTO CO., INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-7645787-B2 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO., INC. (JP) | 2010-01-12 | — | — | US | disclosed |
| EP-1354888-B1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | KISSEI PHARMACEUTICAL (JP) | 2009-05-20 | — | — | EP | disclosed |
| US-20090093419-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | KISSEI PHARMACEUTICAL CO. LTD. (JP) | 2009-04-09 | — | — | US | disclosed |
| EP-1364957-B1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-7465713-B2 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-12-16 | — | — | US | disclosed |
| US-7439232-B2 | Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| US-6815428-B2 | AS DIABETIC-MEDICINE WHICH IS EASY TO SYNTHESIZE, LESS TOXIC AND HAS HIGHER CURATIVE EFFECT | AJINOMOTO CO., INC. (JP) | 2004-11-09 | — | — | US | disclosed |
| US-20040147729-A1 | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2004-07-29 | — | — | US | disclosed |
| US-20040132669-A1 | Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1213296-B1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF | KISSEI PHARMACEUTICAL (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20040063646-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20040006025-A1 | Pyrazole derivatives and diabetic medicine containing them | AJINOMOTO CO. INC (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-1364957-A1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1354888-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-1338603-A1 | NOVEL PYRAZOLE DERIVATIVES AND DIABETES REMEDIES CONTAINING THE SAME | Ajinomoto Co., Inc. (JP) | 2003-08-27 | — | — | EP | disclosed |
| EP-1213296-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2002-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006025-A1 | Pyrazole derivatives and diabetic medicine containing them | SLC5A2, SLC5A1, DPP4 | DAO 2356/4885ALDH1A1 437/4885NPSR1 2499/4885 |
| US-20090093419-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | SLC5A2, SLC5A1, SLC2A4 | DAO 873/4885ALDH1A1 1040/4885NPSR1 1689/4885 |
| US-20040132669-A1 | Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs | SLC5A2, SLC5A1, SLC2A1 | DAO 918/4885ALDH1A1 596/4885NPSR1 2922/4885 |
| US-20100063124-A1 | NEW PYRAZOLE DERIVATIVES AND DIABETIC MEDICINE CONTAINING THEM | DPP4, SLC5A2, SLC5A1 | DAO 1688/4885ALDH1A1 921/4885NPSR1 2467/4885 |
| US-20040063646-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | SLC5A2, SLC5A1, UGGT1 | DAO 946/4885ALDH1A1 1121/4885NPSR1 2090/4885 |
| US-20040147729-A1 | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof | SLC5A1, SLC5A2, UGGT1 | DAO 1139/4885ALDH1A1 352/4885NPSR1 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.